Daewoong Pharm wins Korea patent for human TPO

Published: 2004-08-27 06:57:00

Updated: 2004-08-27 06:57:00

Daewoong Pharm said on August 23 that it acquired a patent for human thrombopoeitin (TPO) in Korea, which relates to a process of manufacturing novel TPO derivatives (codename: DWP-40458) containing sialic acid in a high content, following the successful development of novel TOP in 1999.

Chemo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK